Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.13M$1.13Mderived−47.2% vs Q4 2023 Net Income-$1.22M-$1.22MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$160,589N/M Operating Incomederived-$1,196,036N/M Operating Cash Flowderived$238,474N/M Free Cash Flowderived$218,929— Margins · derivedGross margin-14.2%−10.5 pt vs Q4 2023
Operating margin-105.5%−50.4 pt vs Q4 2023
Net margin-108.0%−50.7 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end